Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning-Reference-Cited by-同舟云学术

Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning

Published:2023-08-10 Issue:11 Volume:58 Page:1203-1208
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Arshad Shanze,Fang Xi^ORCID,Ahn Kwang W.,Kaur Manmeet,Scordo Michael,Sauter Craig S.,Furqan Fateeha,Awan Farrukh T.,Hamadani Mehdi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02071-8.pdf

Reference22 articles.

1. Glass J, Won M, Schultz CJ, Brat D, Bartlett N, Suh J. et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016;34:1620–5. https://doi.org/10.1200/jco.2015.64.8634.

2. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–27. https://doi.org/10.1016/s2352-3026(16)00036-3.

3. Ferreri AJM, Cwynarski K, Pulczynski E, Fox C, Schorb E, Rosee P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510–e523. https://doi.org/10.1016/s2352-3026(17)30174-6.

4. Ferreri AJM, Cwynarski K, Pulczynski E, Fox C, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022;36:1870–8. https://doi.org/10.1038/s41375-022-01582-5.

5. Batchelor T, Giri S, Ruppert AS, Bartlett N, His E, Cheson B, et al. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance). J Clin Oncol. 2021;39:7506–7506. https://doi.org/10.1200/JCO.2021.39.15_suppl.7506.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence-based management of primary and secondary CNS lymphoma;Seminars in Hematology;2023-12